ELOCTATE IV 250, manufactured by Sanofi, contains Efflaloctocog alpha (genetically recombination), a recombinant human coagulation Factor VIII Fc fusion protein used for the treatment and prophylaxis of bleeding in hemophilia A. It is supplied as 250 IU 1 bottle with dissolving liquid (YJ code: 6343442D1022).
ELOCTATE IV 250
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →